Source: Annual Congress 2008 - Cystic fibrosis: new mechanisms, monitoring and treatment tools



Rating:

Share or cite this content

Citations should be made in the following way:
R. Potter, K. Williams, S. Byrne, K. Nikander, R. Hatley (Chichester, United Kingdom; Parsippany, NJ, United States Of America). Precise dosing of five drugs commonly used by patients with cystic fibrosis using an adaptive aerosol delivery system. Eur Respir J 2008; 32: Suppl. 52, 2877

Member's Comments

No comment yet.

Related content which might interest you: Use of a new feedback tool to optimize inhaled aerosol therapy in patients with cystic fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 261s Year: 2006 Nebulised antibiotics with the I-neb adaptive aerosol delivery (AAD) system: Impact on adherence in cystic fibrosis (CF) patients Source: Annual Congress 2012 - Cystic fibrosis (adults and children): risk factors and clinical problems Year: 2012 Improved treatment response to dornase alfa in cystic fibrosis patients using controlled inhalation Source: Eur Respir J 2011; 38: 1328-1335 Year: 2011 Use of an electronic monitoring system to generate objective information on patients’ adherence to taking treatments of a novel inhaled tobramycin solution Source: Annual Congress 2013 –Cystic fibrosis: clinical problems, genetics and microbiology in children Year: 2013 Aerosol delivery aspects within a high-flow therapy system in COPD patients Source: ERJ Open Res, 7 (1) 00422-2020; 10.1183/23120541.00422-2020 Year: 2021 The pharmacokinetic of the main oral antibiotics in children with cystic fibrosis. Source: International Congress 2019 – Treatments, adherence and psychosocial aspects of cystic fibrosis Year: 2019 Variation in lung function as a marker of adherence to oral and inhaled medication in cystic fibrosis Source: Eur Respir J , 49 (3) 1600987; DOI: 10.1183/13993003.00987-2016 Year: 2017 Reduction of treatment time for nebulized treatments using a new adaptive aerosol delivery mode Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008 Inhaled therapy in cystic fibrosis: agents, devices and regimens Source: Breathe 2015; 11:110-118 Year: 2015 Changes in mechanical properties of respiratory system in children with cystic fibrosis during therapy of exacerbation Source: Eur Respir J 2005; 26: Suppl. 49, 612s Year: 2005 Home intravenous antibiotic treatments in cystic fibrosis adult patients Source: Eur Respir J 2002; 20: Suppl. 38, 158s Year: 2002 Formulation of dual modality nanoparticles to enhance tobramycin efficacy in cystic fibrosis Source: Annual Congress 2013 –Cutting edge: drug delivery to the airways Year: 2013 Self-perceived verses electronic monitoring of adherence to nebulised treatment in children with cystic fibrosis - does the use of telehealth system improve nebulisation adherence? Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science Year: 2013 Pulmonary surfactant as drug delivery system to target lung epithelium: new approach for the treatment of epithelial injury after bleomycin challenge Source: International Congress 2018 – Regenerative and anti-fibrotic approaches Year: 2018 Distribution of technetium-99m-labelled QVARTM delivered using an AutohalerTM device in children Source: Eur Respir J 2003; 21: 1007-1011 Year: 2003 Functional respiratory imaging assessment of the aerosol deposition of inhaled levofloxacin in cystic fibrosis lungs Source: Virtual Congress 2021 – Cystic fibrosis Year: 2021 Dose-finding and 24-h monitoring for efficacy and safety of aerosolized Nacystelyn in cystic fibrosis Source: Eur Respir J 2002; 19: 294-302 Year: 2002 Benefit of aerosol therapy with pulmozyme for children with cystic fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 622s Year: 2005 Extent of inhaled drug deposition in mouth-throat and pulmonary airways: A novel biophysical modelling approach for inhaled therapeutics Source: International Congress 2015 – New models for treating airway diseases Year: 2015 The role of inhaled antibiotics in bronchial infection Source: Eur Respir Monogr 2013; 60: 120-126 Year: 2013